Lijun International Pharmaceutical (Holding) Co. Ltd.

23andMe Reports FY2023 Third Quarter Financial Results

Retrieved on: 
Wednesday, February 8, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., Genetics, Machine learning, Annual general meeting, Marketing, PGS, Research, Telehealth, Food, American Society of Human Genetics, Food and Drug Administration, Family, Tax, Society, ASH, Squamous cell carcinoma, Advertising, ATM, Marker beacon, Wilms' tumor, Webcast, Society for Immunotherapy of Cancer, Immunotherapy, Genome, Human genetics, CD200R1, Drug development, EBITDA, Ashkenazi Jews, SAN, National Human Genome Research Institute, Clinical trial, Keith Lemon's LemonAid, FDA, Agricultural Research Service, Consumer service, GSK, Asthma, Interim, Growth, ASHG, Johns Hopkins, SITC, NHGRI, Therapy, Simvastatin, Pharmaceutical industry, Central Europe, Adjustment

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (Q3) of its fiscal year 2023 (FY2023), which ended December 31, 2022. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health risk reports, and in particular the only company the FDA has authorized to provide, without physician involvement, genetic cancer risk reports and medication insights on how individuals may process certain commonly prescribed medications based on their genetics. The Company has also created the world’s largest crowdsourced platform for genetic research, which it is using to pursue drug discovery programs rooted in human genetics across a spectrum of disease areas.

Key Points: 
  • These reports are developed by 23andMe scientists using data and insights gathered from thousands of customers who have consented to participate in our research.
  • “Our fiscal third quarter results reflect solid revenue growth in our consumer business, despite the macro-economic headwinds, and give us confidence to raise our full year financial guidance,” said Joe Selsavage, Interim Chief Financial and Accounting Officer of 23andMe.
  • 23andMe is raising its full year guidance following Q3 FY2023 results.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time on Wednesday, February 8, 2023 to discuss the financial results for Q3 FY2023 and report on business progress.

Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications

Retrieved on: 
Tuesday, December 6, 2022
IPO, NIH, Manuscript, AA, American Association for Cancer Research, Prostate cancer, Immunotherapy, Risk, Doctor of Philosophy, Patient, Cancer, Radiation, SBIR, Research, Precision medicine, Prostate, Medicine, Quality of life, Lijun International Pharmaceutical (Holding) Co. Ltd., AACR, Survival, RT, Cell, Laboratory, Science, Growth, Novel, Mortality, Moonshot, Georgetown University, Pharmaceutical industry

The manuscript, titled "Novel paired normal prostate and prostate cancer model cell systems derived from African American patients," by Dr. Mira Jung was published in Cancer Research Communications, a journal affiliated with the American Association for Cancer Research (AACR), the premier international cancer research society.

Key Points: 
  • The manuscript, titled "Novel paired normal prostate and prostate cancer model cell systems derived from African American patients," by Dr. Mira Jung was published in Cancer Research Communications, a journal affiliated with the American Association for Cancer Research (AACR), the premier international cancer research society.
  • This research project advances research into prostate cancer health disparities for African American men.
  • Cancer Research Communications is an open access peer-reviewed journal that encompasses the full spectrum of research on cancer.
  • Basic, translational, clinical, and population-level cancer research advances all fall within the scope of Cancer Research Communications.

23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season

Retrieved on: 
Thursday, December 1, 2022
COVID-19, 23andMe, Genetics, Lijun International Pharmaceutical (Holding) Co. Ltd., Geography, Depression, Education, SurveyMonkey, Genome, Diet, Census, Health, Therapy, Health insurance, Lithium, Dietary supplement

SUNNYVALE, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported survey results on how US adults are feeling about their health this holiday season. According to the survey*, most people in the US report feeling less stressed or anxious about their health this year compared to earlier in the pandemic, and many have returned to their traditional holiday celebrations.

Key Points: 
  • According to the survey*, most people in the US report feeling less stressed or anxious about their health this year compared to earlier in the pandemic, and many have returned to their traditional holiday celebrations.
  • In this third holiday under the shadow of COVID-19, people appear to have adjusted to the new normal and are more optimistic about their health.
  • However, most people are still concerned about their overall health, with 77 percent of those surveyed indicating they still feel some sort of negativity around their health.
  • Respondents for this survey were selected from people who take surveys on the SurveyMonkey platform each day.

JinkoSolar Schedules 2022 Annual General Meeting to be Held on December 28, 2022

Retrieved on: 
Wednesday, November 23, 2022
NYSE, Annual report, Lijun International Pharmaceutical (Holding) Co. Ltd., Remuneration, Lane, United Arab Emirates, United Kingdom, JKS, Renewable energy, Holding company, Audit, Security (finance)

Only shareholders of record at the close of business on November 28, 2022 (New York time) are entitled to receive notice of and to vote at the Company's annual general meeting or any adjournment or postponement thereof.

Key Points: 
  • Only shareholders of record at the close of business on November 28, 2022 (New York time) are entitled to receive notice of and to vote at the Company's annual general meeting or any adjournment or postponement thereof.
  • JinkoSolar (NYSE: JKS) is one of the largest and most innovative solar module manufacturers in the world.
  • These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements.
  • Among other things, the quotations from management in this press release and the Company's operations and business outlook, contain forward-looking statements.

EQS-News: The NIH Has Given BioRestorative Therapies A Stamp Of Approval

Retrieved on: 
Friday, November 11, 2022
Transfer, Federal, Qualcomm, QCOM, Lijun International Pharmaceutical (Holding) Co. Ltd., Innovation, Small Business Innovation Research, Biomedical engineering, Food, STTR, Diabetes, Advertising, Food and Drug Administration, Research, Adipose tissue, Department, NIH, Small Business Administration, Obesity, Biomedicine, Stem cell, SBIR, NASDAQ, Solution, National Institute, Company, PEG, B cell, Pain scale, Pain, Patient, Small business, National Institutes of Health, Washington University in St. Louis, Map, FDA, Pharmaceutical industry, Bank

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.

Key Points: 
  • BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.
  • This fascinating opportunity presents a study that is highly suggestive of the potential outcomes for which they are currently processing.
  • BioRestorative Therapies Has Joined The Leagues Of 23andMe, Qualcomm and Naviscan
    In September 2021, BioRestorative was awarded a Small Business Technology Transfer (STTR) phase I grant for $256,000.
  • With the recent grants BioRestorative Therapies has received, the NIH has given the company a stamp of approval.

Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors

Retrieved on: 
Tuesday, November 1, 2022
Honda, Survival, Board of directors, Risk, IPO, California State University, Faculty, Cherokee Nation, SEC, Anhui University, Cancer, Karolinska Institute, Research, Board, RT, Tokyo Medical and Dental University, Nasdaq, University of British Columbia, Immunotherapy, National Coalition for Syrian Revolutionary and Opposition Forces, Cherokee, Lijun International Pharmaceutical (Holding) Co. Ltd., University, National Institute of General Medical Sciences, Radiation, Patient, Audit committee, National, Georgetown University School of Medicine, Ecology, Sciences Po, Georgetown University, Quality of life, Chang Gung University, Georgetown University School of Nursing and Health Studies, Moses Austin, Pharmaceutical industry, Nursing

ROCKVILLE, Md., Nov. 1, 2022 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the appointment of Dr. Bette Jacobs to its Board of Directors as an independent director.

Key Points: 
  • ROCKVILLE, Md., Nov. 1, 2022 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the appointment of Dr. Bette Jacobs to its Board of Directors as an independent director.
  • Dr. Jacobs will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
  • A voting member of the Cherokee Nation, Dr. Jacobs has lifetime involvement in advancing equity and diversity programs.
  • "I am excited to welcome Dr. Bette Jacobs to the board at Shuttle Pharmaceuticals," Dr. Anatoly Dritschilo, Chief Executive Officer of Shuttle Pharmaceuticals, said.

23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication

Retrieved on: 
Thursday, October 27, 2022
23andMe, Therapy, Securities Exchange Act of 1934, Security (finance), U.S. Securities and Exchange Commission, Regulation of tobacco by the U.S. Food and Drug Administration, Genomic Health, Stroke, Growth, Terminology, Risk, Genotype, Cholesterol, Food, Lijun International Pharmaceutical (Holding) Co. Ltd., Sumathi Best Television Current Reporting Award, Annual report, List of Dove Medical Press academic journals, Patient, SAMS, Pharmacogenomics, SLCO1B1, GLOBE, PGT, Simvastatin, FDA, SAN, Securities Act of 1933, Drug Quality and Security Act, Genetics, Genome, Pharmaceutical industry

The 510(k) clearance modifies the labeling of the previously authorized 23andMe SLCO1B1 Drug Transport report, removing the need for confirmatory testing and allowing the company to provide interpretive drug information based on genetic factors for simvastatin.

Key Points: 
  • The 510(k) clearance modifies the labeling of the previously authorized 23andMe SLCO1B1 Drug Transport report, removing the need for confirmatory testing and allowing the company to provide interpretive drug information based on genetic factors for simvastatin.
  • Simvastatin is a medication in the statin family of drugs, commonly prescribed to lower cholesterol to help reduce the risk of heart attack and stroke.
  • In 2020, simvastatin was the second-most commonly prescribed statin, and the thirteenth-most commonly prescribed medication overall, in the U.S.* A variation of a particular gene, SLCO1B1, influences the bodys response to simvastatin.
  • 23andMe underwent rigorous analytical validation in order to meet FDA requirements to remove the need for confirmatory testing of the 23andMe pharmacogenetics report for SLCO1B1.

Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Friday, October 14, 2022
LinkedIn, U.S. Securities and Exchange Commission, Securities Act of 1933, Neoplasm, IND, Lijun International Pharmaceutical (Holding) Co. Ltd., SITC, NASDAQ, Investigational New Drug, Twitter, Security (finance), Annual general meeting, Private Securities Litigation Reform Act, Drug discovery, TGF, Company, Industry, Nature, Securities Exchange Act of 1934, COVID-19, Poster, Online gambling, Vaccine, Corbus, Facebook

Investigational New Drug (IND) enabling studies are currently underway with a plan to explore the anti-tumor activity of this agent clinically in 2023.

Key Points: 
  • Investigational New Drug (IND) enabling studies are currently underway with a plan to explore the anti-tumor activity of this agent clinically in 2023.
  • Corbus is an immunology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways.
  • Corbus' current pipeline includes anti-integrin monoclonal antibodies that block activation of TGF and small molecules that activate or inhibit the endocannabinoid system.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Vertiv Announces Date of Third Quarter 2022 Earnings Release and Conference Call

Retrieved on: 
Wednesday, October 12, 2022
Professional Services, Data Management, Technology, Data Analytics, Software, Hardware, Software, NYSE, News, Lijun International Pharmaceutical (Holding) Co. Ltd., Investor relations, Webcast, Solution, VRT, Video game, Vertiv

Vertiv Holdings Co (NYSE: VRT), a global provider of critical digital infrastructure and continuity solutions, today announced it will report its third quarter 2022 results before market open on Wednesday, October 26, 2022.

Key Points: 
  • Vertiv Holdings Co (NYSE: VRT), a global provider of critical digital infrastructure and continuity solutions, today announced it will report its third quarter 2022 results before market open on Wednesday, October 26, 2022.
  • The press release will contain a link to the presentation materials providing a third quarter 2022 update, which will be available on Vertivs website at investors.vertiv.com .
  • Vertivs management team will discuss the results during a conference call the same day, starting at 11 a.m. Eastern Time.
  • A webcast of the live conference call can be accessed in the Investor Relations section of Vertivs website at investors.vertiv.com .

DUNN-EDWARDS CORPORATION ANNOUNCES 2023 COLOR OF THE YEAR

Retrieved on: 
Tuesday, October 4, 2022
Color, Life, McLean, Culture, LOS, Terra rosa, TYO, Multimedia, Drama, LEED, Escapism, Paint, Environment, Empowerment, Creativity, Beauty, Lijun International Pharmaceutical (Holding) Co. Ltd., Fashion, Interior design

LOS ANGELES, Oct. 4, 2022 /PRNewswire/ -- Today, Dunn-Edwards Corporation announced its 2023 Color of the Year as Terra Rosa (DE5096), a scorched-earth, approachable hue with rosy pink tones and a touch of terra-cotta. Its grounding, quiet comfort encourages a life filled with joy. Led by Color Expert + Stylist Sara McLean, Dunn-Edwards takes on an extensive anthropological study of color to annually identify a Color of the Year that is predictive and forward-thinking of the year ahead and beyond.

Key Points: 
  • LOS ANGELES, Oct. 4, 2022 /PRNewswire/ -- Today, Dunn-Edwards Corporation announced its 2023 Color of the Year as Terra Rosa (DE5096), a scorched-earth, approachable hue with rosy pink tones and a touch of terra-cotta.
  • Led by Color Expert + Stylist Sara McLean, Dunn-Edwards takes on an extensive anthropological study of color to annually identify a Color of the Year that is predictive and forward-thinking of the year ahead and beyond.
  • Terra Rosa is represented in the Life in Poetry color palette within the 2023 Color + Design Trends identified by Dunn-Edwards.
  • As a leader in color direction and inspiration, Dunn-Edwards names a Color of the Year to inspire and encourage professionals and consumers to embrace creativity.